Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors Meeting Abstract
| Authors: | Borad, M. J.; Schram, A. M.; Kim, R. D.; Kamath, S. D.; Sahai, V.; Dotan, E.; Kelley, R. K.; Ponz-Sarvise, M.; Oh, D. Y.; Yachnin, J.; Florou, V.; Cassier, P. A.; Park, J. O.; Liao, C. Y.; Millward, M.; Ramirez, F.; Ricard, F. J.; Hollebecque, A.; Subbiah, V.; Goyal, L. |
| Abstract Title: | Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.4009 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4009 -- This meeting was also held virtually -- Source: Cinahl |
